What drove the significant increase in purchased in-process R&D expenses?

The substantial increase in purchased in-process R&D expenses is primarily due to two key acquisitions made during the reporting period: Percutaneous Valve Technologies (PVT) for $125 million, which included an $81.0 million charge for in-process R&D, and the acquisition of technology from ev3, Inc. for $15 million, with a $12.3 million charge for in-process R&D. These acquisitions are focused on developing advanced cardiovascular technologies, particularly percutaneous valve replacement.

Why did the company report a net loss for the nine-month period despite revenue growth?

The net loss of $24.2 million for the nine months ended September 30, 2004, compared to a net income of $60.1 million in the prior year, is largely a result of significant non-cash charges related to the acquisitions. The accounting for in-process research and development (IPR&D) required the immediate expensing of a substantial portion of the acquisition costs. Specifically, the $81.0 million IPR&D charge from the PVT acquisition and the $12.3 million from the ev3 acquisition significantly impacted the reported net income.

How is the company managing its liquidity given the decrease in cash and cash equivalents?

While cash and cash equivalents decreased to $31.0 million at the end of the quarter, down from $61.1 million at year-end 2003, the company has a substantial $500 million revolving credit facility that provides significant financial flexibility. As of September 30, 2004, $119.2 million was outstanding under this facility. The company also utilizes accounts receivable securitization programs. Management believes these sources are sufficient to fund its working capital, capital expenditures, and growth objectives.

What are the key growth drivers for Edwards Lifesciences?

The primary growth driver identified is the Heart Valve Therapy segment, which saw significant increases driven by strong market adoption of advanced products like the Carpentier-Edwards PERIMOUNT Magna valve. The company is also investing heavily in its percutaneous valve programs (like the acquired PVT technology), which are expected to offer less-invasive, breakthrough treatments for cardiovascular diseases, representing future growth opportunities.

EW 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation (EW) reported its third-quarter financial results for the period ending September 30, 2004. The company demonstrated solid top-line growth, with total net sales increasing by 9.1% year-over-year to $224.8 million for the quarter and 9.1% to $694.4 million for the nine-month period. This growth was primarily driven by strong performance in Heart Valve Therapy, up 14.4% sequentially and 14.6% year-to-date, with significant contributions from the PERIMOUNT Magna valve. International sales also showed robust growth, benefiting from favorable foreign currency exchange rates. However, the company reported a net loss of $24.2 million for the nine-month period, a significant decrease from a net income of $60.1 million in the prior year, largely attributable to substantial in-process research and development charges related to strategic acquisitions, notably the acquisition of Percutaneous Valve Technologies (PVT). The balance sheet shows a decrease in cash and cash equivalents to $31.0 million from $61.1 million at the end of the previous year, alongside an increase in long-term debt, reflecting financing for acquisitions. Investors should note the significant investment in future growth through R&D and acquisitions, as evidenced by the substantial in-process R&D charges. While top-line growth is encouraging, the resulting net loss for the year-to-date period warrants attention. The company's liquidity appears adequate, with a substantial revolving credit facility available. Management's focus on strategic acquisitions like PVT and ev3, Inc.'s percutaneous mitral valve repair program highlights a commitment to innovation and market expansion in advanced cardiovascular disease treatments. The company also faces ongoing legal proceedings but management believes they will not materially impact the financial position.

Key Highlights

1Total net sales increased 9.1% year-over-year to $224.8 million for the third quarter and 9.1% to $694.4 million for the nine months ended September 30, 2004.
2Heart Valve Therapy segment sales grew significantly, up 14.4% for the quarter and 14.6% year-to-date, driven by strong adoption of the PERIMOUNT Magna valve.
3A net loss of $24.2 million was reported for the nine months ended September 30, 2004, compared to a net income of $60.1 million in the prior year, primarily due to significant in-process R&D charges from acquisitions.
4The company completed significant acquisitions, including Percutaneous Valve Technologies (PVT) for $125 million and ev3, Inc.'s percutaneous mitral valve repair program for $15 million, incurring substantial in-process R&D charges ($81.0 million and $12.3 million, respectively).
5Cash and cash equivalents decreased to $31.0 million as of September 30, 2004, from $61.1 million at December 31, 2003, reflecting cash used for acquisitions and capital expenditures.
6The company has a $500 million revolving credit facility, with $119.2 million outstanding as of September 30, 2004, indicating sufficient liquidity.
7Gross profit margin improved to 60.9% in the quarter and 59.8% year-to-date, up from 57.8% and 58.3%, respectively, in the prior year, driven by a favorable product mix and operational efficiencies.

Edwards Lifesciences Corp Quarterly Report for Q3 Ended Sep 30, 2004

Summary

Key Highlights

Frequently Asked Questions